Sanofi announced data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1, GLP-1, receptor agonist, decreased HbA1c by reducing PPG, postprandial glucose, daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents, OADs. Lixisenatide is for the treatment of adults with type 2 diabetes mellitus. This data was presented at the American Diabetes Association 73rd Scientific Sessions in Chicago.